BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18593984)

  • 1. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.
    Bell DW; Brannigan BW; Matsuo K; Finkelstein DM; Sordella R; Settleman J; Mitsudomi T; Haber DA
    Clin Cancer Res; 2008 Jul; 14(13):4079-84. PubMed ID: 18593984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
    Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
    PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas.
    Toh CK; Ahmad B; Soong R; Chuah KL; Tan SH; Hee SW; Leong SS; Tan EH; Lim WT
    J Thorac Oncol; 2010 Jan; 5(1):17-22. PubMed ID: 19875972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.
    Zhou W; Christiani DC
    Chin J Cancer; 2011 May; 30(5):287-92. PubMed ID: 21527061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.
    Liam CK; Leow HR; How SH; Pang YK; Chua KT; Lim BK; Lai NL; Kuan YC; Pailoor J; Rajadurai P
    Asian Pac J Cancer Prev; 2014; 15(1):321-6. PubMed ID: 24528049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
    Leidner RS; Fu P; Clifford B; Hamdan A; Jin C; Eisenberg R; Boggon TJ; Skokan M; Franklin WA; Cappuzzo F; Hirsch FR; Varella-Garcia M; Halmos B
    J Clin Oncol; 2009 Nov; 27(33):5620-6. PubMed ID: 19786660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
    Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
    Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Impacts of
    Lee KL; Lai TC; Wang YC; Shih PC; Yang YC; Tsao TC; Liu TC; Wen YC; Chang LC; Yang SF; Chien MH
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33802737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and types of
    Lemine Sow M; El Yacoubi H; Moukafih B; Balde S; Akimana G; Najem S; El Khoyaali S; Abahssain H; Chaibi A; Zeb Khan S; Trapani D; Benzekri A; Ghaouti M; Gamra L; Mestari A; Kettani F; Rahali Y; Mrabti H; Elghissassi I; Errihani H
    Tumori; 2021 Aug; 107(4):335-340. PubMed ID: 33079008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of hOGG1-Cys variants with occurrence of p53 and EGFR deletion mutations in non-small cell lung cancer.
    Chen MJ; Shen CJ; Wang L; Chen PM; Chen CY; Lee H
    Thorac Cancer; 2021 Feb; 12(4):534-538. PubMed ID: 33372419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).
    Ramadhan HH; Taaban DF; Hassan JK
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):591-596. PubMed ID: 33639678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.
    Choi YL; Sun JM; Cho J; Rampal S; Han J; Parasuraman B; Guallar E; Lee G; Lee J; Shim YM
    PLoS One; 2013; 8(2):e56011. PubMed ID: 23468851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
    Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
    J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
    J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).
    Arrieta O; Cardona AF; Martín C; Más-López L; Corrales-Rodríguez L; Bramuglia G; Castillo-Fernandez O; Meyerson M; Amieva-Rivera E; Campos-Parra AD; Carranza H; Gómez de la Torre JC; Powazniak Y; Aldaco-Sarvide F; Vargas C; Trigo M; Magallanes-Maciel M; Otero J; Sánchez-Reyes R; Cuello M
    J Thorac Oncol; 2015 May; 10(5):838-843. PubMed ID: 25634006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.